Syros Pharmaceuticals (SYRS) Tops Q1 EPS by 7c

Syros Pharmaceuticals (NASDAQ: SYRS) reported Q1 EPS of ($0.40), $0.07 better than the analyst estimate of ($0.47). Revenue for the quarter came in at $5.5 million versus the consensus estimate of $4.92 million.

For earnings history and earnings-related data on Syros Pharmaceuticals (SYRS) click here.

You May Also Be Interested In

• FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
• Cerebras Systems (CBRS) Misses Q1 EPS, Revenues Beat
• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI